DRG Market Assessment 보고서

Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Clarivate Epidemiology’s coverage of actinic keratosis (AK) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…

Clarivate Epidemiology’s coverage of acne comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of acne for each country, as well…

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…

Clarivate’s primary market research explores how PCPs / pain specialists in the United States navigate the current treatment of chronic pain, with a focus on chronic back pain and OA pain.

A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in early stages of the disease, today’s treatment paradigm is suboptimal owing to considerable pill burden, a…